SecBot SecBot

TRDA

Entrada Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001689375 Biotech & Drug Discovery
$5.00 −0.09 (−1.77%)
Nov 16 4:00 PM ET · prev $5.09
Market cap
$202.4M
Micro cap
Median target
$20.00
+300% · range $10.00–25.00
1 year
−41.0%
from $8.47 · Nov 17
30 days
+3.7%
from $4.82
52-week range
$4.37–16.03
−69% from high · low Oct 16
Avg volume 20D
508.6K
shares / day
Short interest
2.81M
≈7.2% of shares · −14.2%
Days to cover
6.9
at average volume
Insider net
−$11.3M
1 buyer · 7 sellers · since Mar 10
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
20
analyzed by SecBot
SecBot read MIXED 9 reports · 90 days
Balance 1 bearish · 1 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 5/9

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $29.3K at an average $5.86. 7 insiders sold $11.3M. Price is 15% below their cost.

  • InstitutionsBULLISH

    Q3 2026: 24 added (0 new), 8 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.873 → −$1.060 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −14.2% to 2.81M shares. 6.9 days to cover, ≈7.2% of shares.

  • TrendDOWNTREND

    10% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD3,237,107$20.6M
UBS Group AGDOUBLED624,220$4.0M
MORGAN STANLEYDOUBLED386,243$2.5M
BNP PARIBAS FINANCIAL MARKETSDOUBLED232,569$1.5M
Qube Research & Technologies LtdDOUBLED150,225$953.9K
Jump Financial, LLCDOUBLED82,259$522.3K
BARCLAYS PLCDOUBLED70,625$448.5K
RHUMBLINE ADVISERSADD55,055$349.6K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Jun 2026
12-month targets · 4 analysts

Price is below the lowest target. Median implies +300%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Jun 8, 2026Guggenheim
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$29.3K
bought · 1 insider
$11.3M
sold · 7 insiders
−14.7%
vs their $5.86 cost
DateInsiderTypeValue
Sep 9, 2026
MPM BioVentures 2014, L.P.
10%+ Owner
Sep 9, 2026
SELL$205.6K
Sep 9, 2026
MPM BIOVENTURES 2018, L.P.
10%+ Owner
Sep 9, 2026
SELL$205.6K
Sep 8, 2026
MPM BioVentures 2014, L.P.
10%+ Owner
Sep 8, 2026
SELL$1.4M
Sep 8, 2026
MPM BIOVENTURES 2018, L.P.
10%+ Owner
Sep 8, 2026
SELL$1.4M
Sep 4, 2026
MPM BioVentures 2014, L.P.
10%+ Owner
Sep 4, 2026
SELL$273.7K
Sep 4, 2026
MPM BIOVENTURES 2018, L.P.
10%+ Owner
Sep 4, 2026
SELL$273.7K
Sep 3, 2026
MPM BIOVENTURES 2018, L.P.
10%+ Owner
Sep 3, 2026
SELL$231.3K
Sep 3, 2026
MPM BioVentures 2014, L.P.
10%+ Owner
Sep 3, 2026
SELL$231.3K

Earnings setup

Estimates
−$1.06
EPS estimate, this quarter
−21%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.06-$1.15–-$0.96-20.1%$1.4M
Next Q-$0.76-$1.10–-$0.12+0.7%$18.3M
Current FY-$3.96-$4.05–-$3.86-4.4%$4.0M
Next FY-$3.40-$4.16–-$2.90-12.9%$20.4M

Short side

FINRA· Oct 30, 2026
2,807,309
shares short
-14.2%
vs prior settlement
6.9
days to cover
≈7.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 Earnings calendar
TRDA Q3 2026 Earnings Before Market Open · 2026-11-10
Nov 5, 2026 SEC
The company highlighted positive safety data from ELEVATE-45-201 Cohort 1 and progress across its DMD clinical…
8-K · Impact 4/10
Nov 5, 2026 SEC
Entrada Therapeutics reported Q3 2026 net loss of $39.7M ($0.94 per share), narrower than the $44.1M loss in Q3 2025…
PRESS-RELEASE · Impact 4/10
Oct 14, 2026 SEC
Entrada Therapeutics announced positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-45-201 study of…
8-K · Impact 6/10
Sep 30, 2026 Inst.
BlackRock, Inc. · ADD
3,237,107 shares ($20.6M)
Sep 30, 2026 Inst.
UBS Group AG · DOUBLED
624,220 shares ($4.0M)
Sep 9, 2026 Insider
MPM BioVentures 2014, L.P. sold 28,837 shares
10%+ Owner @ $7.13 ($205.6K)
Sep 9, 2026 Insider
MPM BIOVENTURES 2018, L.P. sold 28,837 shares
10%+ Owner @ $7.13 ($205.6K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

20 filings · 1 press release · 1 bullish · 4 bearish · 1 mixed · 14 neutral
All TRDA filing & press-release reports (21)